ArticleClinical cardiology2018
Growth differentiation factor 15 is associated with left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.
Article in Clinical cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Growth differentiation factor-15 and the risk of cardiovascular diseases and all-cause mortality: A meta-analysis of prospective studies.Clinical cardiology · 2019Pooled it
- Serum-Soluble ST2 Is a Novel Biomarker for Evaluating Left Atrial Low-Voltage Zone in Paroxysmal Atrial Fibrillation.Medical science monitor : international medical journal of experimental and clinical research · 2020Trial
- Molecular Biomarkers Linking Psoriasis and Cardiovascular Disease: Current Evidence and Clinical Perspectives.International journal of molecular sciences · 2026Review
- Angiopoietin-2 and Growth Differentiation Factor-15 as Predictors of Device-Detected Atrial Fibrillation Burden.Biomedicines · 2026Article
- Improving stroke risk prediction in atrial fibrillation with circulating biomarkers: the CHAJournal of thrombosis and haemostasis : JTH · 2025Article
- Circulating biomarkers and ischemic stroke risk in adults with atrial fibrillation taking anticoagulation: the Reasons for Geographic And Racial Differences in Stroke study.Journal of thrombosis and haemostasis : JTH · 2025Article
- [Different levels and clinical significance of growth differentiation factor-15 in patients with atrial fibrillation].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Impaired fibrinolysis in patients with atrial fibrillation and elevated circulating lipopolysaccharide.Journal of thrombosis and thrombolysis · 2024Article
- Evaluation of New Potential Inflammatory Markers in Patients with Nonvalvular Atrial Fibrillation.International journal of molecular sciences · 2023Article
- Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure.Journal of diabetes · 2022Review
- The Potential Role of Growth Differentiation Factor 15 in COVID-19: A Corollary Subjective Effect or Not?Diagnostics (Basel, Switzerland) · 2022Review
- Laboratory medicine in pandemic of COVID-19.Biochemia medica · 2022Article
- Plasma growth differentiation factor-15 in patients with "lone" atrial fibrillation.Journal of clinical laboratory analysis · 2022Article
- Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation.Journal of clinical medicine · 2022Review
- GDF-15 as a Biomarker in Cardiovascular Disease.Arquivos brasileiros de cardiologia · 2021Review
- A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation.Frontiers in cardiovascular medicine · 2021Review
- Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation.Clinical research in cardiology : official journal of the German Cardiac Society · 2020Article
- Atrial Myopathy.JACC. Basic to translational science · 2019Review
- Growth differentiation factor 15 is associated with left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.Clinical cardiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is evidence suggesting that growth differentiation factor 15 (GDF-15) appears to be associated with stroke in patients with atrial fibrillation (AF). AF-related thromboembolic stroke is predominantly attributed to the thrombus from the left atrium (LA) or left atrial appendage (LAA). HYPOTHESIS: GDF-15 is related to LA/LAA thrombus in nonvalvular AF (NVAF) patients.
methodsA total of 894 patients with NVAF without anticoagulation therapy were included in this study. All patients routinely underwent transesophageal echocardiography for detection of LA/LAA thrombus. GDF-15 was measured by enzyme-linked immunosorbent assay. Logistic regression models were used to test for association.
resultsLA/LAA thrombus was detected by transesophageal echocardiography in 69 (7.72%) patients with AF. The GDF-15 levels in the patients with LA/LAA thrombus were significantly higher than those without LA/LAA thrombus (log
conclusionsElevated GDF-15 indicated a significantly increased risk for LA/LAA thrombus in NVAF patients. Thus, GDF-15 might be a potentially useful adjunct in discriminating LA/LAA thrombus in NVAF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.